POINT RICHMOND, Calif., July 29, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Wednesday, August 7, 2013, at 4:30 p.m. Eastern Time to discuss its second quarter 2013 financial results. The conference call will follow the release of the Transcept second quarter 2013 financial results after the close of market that day.
Conference Call Information
Date: Wednesday, August 7, 2013
Time: 4:30 p.m. ET
Dial-in (U.S.): (877) 638-4558
Dial-in (International): (914) 495-8537
A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website shortly after the conclusion of the call and will be available through September 30, 2013.
About Transcept Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.
Contact: Transcept Pharmaceuticals, Inc. Leone Patterson Vice President and Chief Financial Officer (510) 215-3512 email@example.com
SOURCE Transcept Pharmaceuticals, Inc.